Sign Up Today and Learn More About Halia Therapeutics Stock
Invest in or calculate the value of your shares in Halia Therapeutics or other pre-IPO companies through EquityZen's platform.
Halia Therapeutics Stock (HATH)
Halia Therapeutics is a biopharmaceutical company manufacturing therapies to improve the lives of patients with inflammatory disorders.
About Halia Therapeutics Stock
Founded
2017
Headquarters
Lehi, UT, US
Industries
Science and Engineering, Health Care, Biotechnology
Halia Therapeutics Press Mentions
Stay in the know about the latest news on Halia Therapeutics
Pharmaceutical compositions for inhibitors of nek7 kinase
patents • Apr 02, 2025
Polymorphs of nek 7 inhibitors
patents • Apr 02, 2025
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
biospace • Mar 12, 2025
Halia Therapeutics Secures Novo Nordisk Golden Ticket to Accelerate Development of Chronic Inflammation Treatments
techbuzznews • Mar 12, 2025
Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
prnewswire • Mar 11, 2025
Halia Therapeutics Management
Leadership team at Halia Therapeutics
Vice President Regulatory Affairs
Lisa Shamon
CEO
David J. Bearss
Join now and verify your accreditation status to gain access to:
- Halia Therapeutics Current Valuation
- Halia Therapeutics Stock Price
- Halia Therapeutics Management
- Available deals in Halia Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Halia Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Halia Therapeutics Revenue and Financials
- Halia Therapeutics Highlights
- Halia Therapeutics Business Model
- Halia Therapeutics Risk Factors
- Halia Therapeutics Research Report from SACRA Research
Trading Halia Therapeutics Stock
How to invest in Halia Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Halia Therapeutics through EquityZen funds. These investments are made available by existing Halia Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Halia Therapeutics stock?
Shareholders can sell their Halia Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
